Idexx Laboratories (IDXX) Cash & Equivalents (2009 - 2026)

Idexx Laboratories' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $200.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 22.3% year-over-year to $200.5 million; the TTM figure through Mar 2026 stood at $200.5 million (up 22.3% YoY), while the FY2025 annual figure was $180.1 million, down 37.53% from the prior year.
• Cash & Equivalents was $200.5 million for Q1 2026 at Idexx Laboratories, up from $180.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $453.9 million in Q4 2023 to a low of $99.2 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $227.9 million across 5 years, with a median of $200.5 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents soared 303.33% in 2023, then slumped 59.01% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $112.5 million in 2022, then surged by 303.33% to $453.9 million in 2023, then tumbled by 36.5% to $288.3 million in 2024, then sank by 37.53% to $180.1 million in 2025, then increased by 11.36% to $200.5 million in 2026.
• The last three Cash & Equivalents figures came in at $200.5 million (Q1 2026), $180.1 million (Q4 2025), and $208.2 million (Q3 2025), per Business Quant data.